Syndax Pharmaceuticals, Inc., a privately held oncology company, reports that Briggs W. Morrison, MD is joining the company as chief executive officer and a member of the board of directors, and that Michael A. Metzger is joining the company as president and chief operating officer. Dr. Morrison joins Syndax from AstraZeneca, where he was executive vice president, global medicines development and chief medical officer. Mr. Metzger joins from Regado Biosciences, where he served as president and chief executive officer through the company’s strategic merger with Tobira Therapeutics.
As executive vice president, global medicines development and chief medical officer at AstraZeneca from 2012 to 2015, Dr. Morrison led the company’s global, late-stage development organization and served as a member of the AstraZeneca senior executive team. Prior to joining AstraZeneca, Dr. Morrison held a number of positions at Pfizer from 2007 to 2012 that culminated in his appointment as head, medical affairs, safety, and regulatory affairs for Pfizer’s human health business. He previously served in roles of increasing responsibility at Merck Research Laboratories from 1995 to 2007, where he was ultimately appointed to the role of vice president, clinical sciences, oncology, responsible for clinical development of all novel anti-cancer drugs. Dr. Morrison is chairman of the board of Transcelerate, an industry-funded company charged with improving aspects of clinical trials, a member of the Executive
Committee of CTTI (the Clinical Trials Transformation Initiative sponsored by FDA) and is on the board of ACRES (Alliance for Clinical Research Excellence and Safety).
Source: Syndax Pharmaceuticals